<?xml version="1.0" encoding="UTF-8"?>
<ref id="B32-jof-07-00058">
 <label>32.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Egan</surname>
    <given-names>A.G.</given-names>
   </name>
   <name>
    <surname>Blind</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Dunder</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>de Graeff</surname>
    <given-names>P.A.</given-names>
   </name>
   <name>
    <surname>Hummer</surname>
    <given-names>B.T.</given-names>
   </name>
   <name>
    <surname>Bourcier</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Rosebraugh</surname>
    <given-names>C.</given-names>
   </name>
  </person-group>
  <article-title>Pancreatic Safety of Incretin-Based Drugs-Fda and Ema Assessment</article-title>
  <source>N. Engl. J. Med.</source>
  <year>2014</year>
  <volume>370</volume>
  <fpage>794</fpage>
  <lpage>797</lpage>
  <pub-id pub-id-type="doi">10.1056/NEJMp1314078</pub-id>
  <pub-id pub-id-type="pmid">24571751</pub-id>
 </element-citation>
</ref>
